Advertisement

Calcified Tissue International

, Volume 94, Issue 6, pp 580–589 | Cite as

Incidence Rates and Trends of Hip/Femur Fractures in Five European Countries: Comparison Using E-Healthcare Records Databases

  • G. RequenaEmail author
  • V. Abbing-Karahagopian
  • C. Huerta
  • M. L. De Bruin
  • Y. Alvarez
  • M. Miret
  • U. Hesse
  • H. Gardarsdottir
  • P. C. Souverein
  • J. Slattery
  • C. Schneider
  • M. Rottenkolber
  • S. Schmiedl
  • M. Gil
  • M. C. H. De Groot
  • A. Bate
  • A. Ruigómez
  • L. A. García Rodríguez
  • S. Johansson
  • F. de Vries
  • D. Montero
  • R. Schlienger
  • R. Reynolds
  • O. H. Klungel
  • F. J. de AbajoEmail author
Original Research

Abstract

Hip fractures represent a major public health challenge worldwide. Multinational studies using a common methodology are scarce. We aimed to estimate the incidence rates (IRs) and trends of hip/femur fractures over the period 2003–2009 in five European countries. The study was performed using seven electronic health-care records databases (DBs) from Denmark, The Netherlands, Germany, Spain, and the United Kingdom, based on the same protocol. Yearly IRs of hip/femur fractures were calculated for the general population and for those aged ≥50 years. Trends over time were evaluated using linear regression analysis for both crude and standardized IRs. Sex- and age-standardized IRs for the UK, Netherlands, and Spanish DBs varied from 9 to 11 per 10,000 person-years for the general population and from 22 to 26 for those ≥50 years old; the German DB showed slightly higher IRs (about 13 and 30, respectively), whereas the Danish DB yielded IRs twofold higher (19 and 52, respectively). IRs increased exponentially with age in both sexes. The ratio of females to males was ≥2 for patients aged ≥70–79 years in most DBs. Statistically significant trends over time were only shown for the UK DB (CPRD) (+0.7 % per year, P < 0.01) and the Danish DB (−1.4 % per year, P < 0.01). IRs of hip/femur fractures varied greatly across European countries. With the exception of Denmark, no decreasing trend was observed over the study period.

Keywords

Hip fracture Incidence rate Electronic health-care record European country 

Notes

Acknowledgments

The research leading to these results was conducted as part of the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium; www.imi-protect.eu) which is a public–private partnership coordinated by the European Medicines Agency. The authors thank the excellent collaboration of physicians in the participating countries, whose contribution in recording their professional practice with high-quality standards made possible the availability of databases used in this research. M. L. De Bruin is employed by Utrecht University as a senior researcher conducting research under the umbrella of the WHO Collaborating Centre for pharmaceutical policy and regulation. This center receives no direct funding or donations from private parties, including the pharmaceutical industry. Research funding from public–private partnerships, e.g., IMI, TI Pharma (www.tipharma.nl), is accepted under the condition that no company-specific product or company-related study is conducted. The center has received unrestricted research funding from public sources, e.g., the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the EU 7th Framework Program (FP7), the Dutch Medicines Evaluation Board (MEB), and the Dutch Ministry of Health. The Escher Project is a project of the Top Institute Pharma (TI Pharma), a public–private partnership of the Dutch Government, academia, and pharmaceutical companies. The Escher Project focuses on regulatory science. The PROTECT project is a collaborative European project that comprises a program to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. The projects within the Escher Project and the PROTECT project are of a general nature and do not involve specific companies, products, or therapeutic areas. M. Miret was a Merck employee at the time this research was done; she is not currently working there. C. Schneider received an unconditional grant from Merck Serono, Geneva. S. Schmiedl received honoraria for a lecture from a German pharmaceutical company (Rottapharm Madaus, Cologne, Germany). M. C. H. De Groot received unrestricted funding for pharmacoepidemiological research from the Dutch private–public Top Institute Pharma. A. Bate is a Pfizer employee. A. Ruigómez and L. A. García-Rodríguez are employed by CEIFE, which has received research funding from AstraZeneca R&D (Mölndal, Sweden) and Bayer Pharma (Berlin, Germany). L. A. García-Rodríguez has also served as a speaker and an advisory board member for the above-mentioned companies. S. Johansson is an Astra Zeneca employee. R. Schlienger is a full-term Novartis employee and owns Novartis shares. R. Reynolds is an employee and a stockholder of Pfizer. O. H. Klungel received unrestricted funding for pharmacoepidemiological research from the Dutch private–public Top Institute Pharma.

Funding

The PROTECT project has received support from the Innovative Medicines Initiative Joint Undertaking (IMI JU; www.imi.europa.eu) under Grant 115004, resources of which are composed of financial contributions from the European Union’s Seventh Framework Programme (FP7/2007–2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies’ in-kind contributions. In addition, as a special form of the IMI JU grant, Utrecht University and Alcalá University received a direct financial contribution from Pfizer and AstraZeneca, respectively. M. Miret, A. Bate, R. Schlienger, S. Johansson, and R. Reynolds belong to EFPIA member companies in the IMI JU, and costs related to their part in the research were carried by the respective company as in-kind contributions under the IMI JU scheme. The views expressed are those of the authors only and not of their respective institutions or companies.

Supplementary material

223_2014_9850_MOESM1_ESM.pdf (475 kb)
Supplementary material 1 (PDF 474 kb)

References

  1. 1.
    Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23(9):2239–2256PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    International Osteoporosis Foundation (2008) Osteoporosis in the European Union in 2008: ten years of progress and ongoing challenges. http://www.sante.public.lu/publications/maladies-traitements/osteoporose/osteoporosis-eu-2008/osteoporosis-eu-2008.pdf. Accessed 2 Oct 2012
  3. 3.
    Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767PubMedCrossRefGoogle Scholar
  4. 4.
    Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, Quine S (2000) Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 320(7231):341–346PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Polinder S, Meerding WJ, van Baar ME, Toet H, Mulder S, van Beeck EF, EUROCOST Reference Group (2005) Cost estimation of injury-related hospital admissions in 10 European countries. J Trauma 59(6):1283–1291PubMedCrossRefGoogle Scholar
  6. 6.
    Kanis J, on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health care level. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Accessed Nov 2012
  7. 7.
    Mann E, Meyer G, Haastert B, Icks A (2010) Comparison of hip fracture incidence and trends between Germany and Austria 1995–2004: an epidemiological study. BMC Public Health 10:46PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Hernandez JL, Olmos JM, Alonso MA, Gonzalez-Fernandez CR, Martinez J, Pajaron M, Llorca J, Gonzalez-Macias J (2006) Trend in hip fracture epidemiology over a 14-year period in a Spanish population. Osteoporos Int 17(3):464–470PubMedCrossRefGoogle Scholar
  9. 9.
    Lyritis GP, Rizou S, Galanos A, Makras P (2013) Incidence of hip fractures in Greece during a 30-year period: 1977–2007. Osteoporos Int 24:1579–1585PubMedCrossRefGoogle Scholar
  10. 10.
    Korhonen N, Niemi S, Parkkari J, Sievanen H, Palvanen M, Kannus P (2013) Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010. Osteoporos Int 24:1599–1603PubMedCrossRefGoogle Scholar
  11. 11.
    Lakatos P, Balogh A, Czerwinski E, Dimai HP, Hans D, Holzer G, Lorenc RS, Palicka V, Obermayer-Pietsch B, Stepan J, Takacs I, Resch H (2011) New considerations on the management of osteoporosis in central and eastern Europe (CEE): summary of the “3rd summit on osteoporosis-CEE”, November 2009, Budapest, Hungary. Arch Osteoporos 6(1–2):1–12PubMedCrossRefGoogle Scholar
  12. 12.
    Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22(5):1277–1288PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Abbing-Karahagopian V, Kurz X, de Vries F, van Staa T, Alvarez Y, Hesse U, et al (2013) Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Curr Clin Pharmacol, in pressGoogle Scholar
  14. 14.
    Balasegaram S, Majeed A, Fitz-Clarence H (2001) Trends in hospital admissions for fractures of the hip and femur in England, 1989–1990 to 1997–1998. J Public Health Med 23(1):11–17PubMedCrossRefGoogle Scholar
  15. 15.
    Lalmohamed A, Welsing PM, Lems WF, Jacobs JW, Kanis JA, Johansson H, de Boer A, de Vries F (2012) Calibration of FRAX® 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporos Int 23(3):861–869PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17(12):1726–1733PubMedCrossRefGoogle Scholar
  17. 17.
    Giversen IM (2006) Time trends of age-adjusted incidence rates of first hip fractures: a register-based study among older people in Viborg County, Denmark, 1987–1997. Osteoporos Int 17(4):552–564PubMedCrossRefGoogle Scholar
  18. 18.
    Wu TY, Jen MH, Bottle A, Liaw CK, Aylin P, Majeed A (2011) Admission rates and in-hospital mortality for hip fractures in England 1998 to 2009: time trends study. J Public Health (Oxf) 33(2):284–291CrossRefGoogle Scholar
  19. 19.
    Pages-Castella A, Carbonell-Abella C, Aviles FF, Alzamora M, Baena-Diez JM, Laguna DM, Nogues X, Diez-Perez A, Prieto-Alhambra D (2012) Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study. BMC Musculoskelet Disord 13:79PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Goettsch WG, de Jong RB, Kramarz P, Herings RM (2007) Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study. Pharmacoepidemiol Drug Saf 16(2):166–172PubMedCrossRefGoogle Scholar
  21. 21.
    Icks A, Haastert B, Wildner M, Becker C, Meyer G (2008) Trend of hip fracture incidence in Germany 1995–2004: a population-based study. Osteoporos Int 19(8):1139–1145PubMedCrossRefGoogle Scholar
  22. 22.
    Dhanwal DK, Dennison EM, Harvey NC, Cooper C (2011) Epidemiology of hip fracture: worldwide geographic variation. Indian J Orthop 45(1):15–22PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Johnell O, Borgstrom F, Jonsson B, Kanis J (2007) Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos Int 18(3):333–337PubMedCrossRefGoogle Scholar
  24. 24.
    Elffors I, Allander E, Kanis JA, Gullberg B, Johnell O, Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G et al (1994) The variable incidence of hip fracture in southern Europe: the MEDOS study. Osteoporos Int 4(5):253–263PubMedCrossRefGoogle Scholar
  25. 25.
    Fretland S, Kruger O (1998) Femoral neck fractures in Nord-Trondelag 1988–95. Incidence differences between winter and summer months [in Norwegian]. Tidsskr Nor Laegeforen 118(1):34–36PubMedGoogle Scholar
  26. 26.
    Gronskag AB, Forsmo S, Romundstad P, Langhammer A, Schei B (2010) Incidence and seasonal variation in hip fracture incidence among elderly women in Norway. The HUNT study. Bone 46(5):1294–1298PubMedCrossRefGoogle Scholar
  27. 27.
    Poole KE, Compston JE (2006) Osteoporosis and its management. BMJ 333(7581):1251–1256PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ 315(7102):221–225PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Johnell O, Gullberg B, Allander E, Kanis JA (1992) The apparent incidence of hip fracture in Europe: a study of national register sources. MEDOS study group. Osteoporos Int 2(6):298–302PubMedCrossRefGoogle Scholar
  30. 30.
    Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8(6):611–617PubMedCrossRefGoogle Scholar
  31. 31.
    Tafuri S, Martinelli D, Balducci MT, Fortunato F, Prato R, Germinario C (2008) Epidemiology of femoral neck fractures in Puglia (Italy): an analysis of existing data. Ig Sanita Pubbl 64(5):623–636PubMedGoogle Scholar
  32. 32.
    Nilson F, Moniruzzaman S, Gustavsson J, Andersson R (2012) Trends in hip fracture incidence rates among the elderly in Sweden 1987–2009. J Public Health (Oxf) 35(1):125–131Google Scholar
  33. 33.
    Adams AL, Shi J, Takayanagi M, Dell RM, Funahashi TT, Jacobsen SJ (2012) Ten-year hip fracture incidence rate trends in a large California population, 1997–2006. Osteoporos Int 24(1):373–376PubMedCrossRefGoogle Scholar
  34. 34.
    Pasco JA, Brennan SL, Henry MJ, Nicholson GC, Sanders KM, Zhang Y, Kotowicz MA (2011) Changes in hip fracture rates in southeastern Australia spanning the period 1994–2007. J Bone Miner Res 26(7):1648–1654PubMedCrossRefGoogle Scholar
  35. 35.
    Leslie WD, Sadatsafavi M, Lix LM, Azimaee M, Morin S, Metge CJ, Caetano P (2011) Secular decreases in fracture rates 1986–2006 for Manitoba, Canada: a population-based analysis. Osteoporos Int 22(7):2137–2143PubMedCrossRefGoogle Scholar
  36. 36.
    Holt G, Smith R, Duncan K, Hutchison JD, Reid D (2009) Changes in population demographics and the future incidence of hip fracture. Injury 40(7):722–726PubMedCrossRefGoogle Scholar
  37. 37.
    Greene D, Dell RM (2010) Outcomes of an osteoporosis disease-management program managed by nurse practitioners. J Am Acad Nurse Pract 22(6):326–329PubMedCrossRefGoogle Scholar
  38. 38.
    EU Commission, Executive Agency for Health and Consumers (EAHC) (2009) PASEO (physical activity among sedentary older people). http://www.paseonet.org/the_project.html. Accessed Nov 2012
  39. 39.
    Huerta CA-KV, Requena G, Oliva B, Alvarez Y, et al (2013) Prevalence of use of benzodiazepines and related drugs in seven European databases: a cross-national descriptive study from the PROTECT-EU project. Presented at the 29th international conference on pharmacoepidemiology and therapeutic risk management, Montreal, 25–28 August 2013Google Scholar
  40. 40.
    Garcia Rodriguez LA, Ruigomez A (2010) Case validation in research using large databases. Br J Gen Pract 60(572):160–161PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Evans JG, Seagroatt V, Goldacre MJ (1997) Secular trends in proximal femoral fracture, Oxford record linkage study area and England 1968–86. J Epidemiol Community Health 51(4):424–429PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728–1737PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • G. Requena
    • 1
    Email author
  • V. Abbing-Karahagopian
    • 2
  • C. Huerta
    • 3
  • M. L. De Bruin
    • 2
  • Y. Alvarez
    • 4
  • M. Miret
    • 5
  • U. Hesse
    • 6
  • H. Gardarsdottir
    • 2
    • 7
  • P. C. Souverein
    • 2
  • J. Slattery
    • 4
  • C. Schneider
    • 8
  • M. Rottenkolber
    • 9
  • S. Schmiedl
    • 10
    • 11
  • M. Gil
    • 3
  • M. C. H. De Groot
    • 2
  • A. Bate
    • 12
  • A. Ruigómez
    • 13
  • L. A. García Rodríguez
    • 13
  • S. Johansson
    • 14
  • F. de Vries
    • 2
    • 15
    • 16
  • D. Montero
    • 3
  • R. Schlienger
    • 17
  • R. Reynolds
    • 18
  • O. H. Klungel
    • 2
    • 19
  • F. J. de Abajo
    • 1
    • 20
    Email author
  1. 1.Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health SciencesUniversity of AlcaláMadridSpain
  2. 2.Utrecht Institute for Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical PharmacologyUtrecht UniversityUtrechtThe Netherlands
  3. 3.Division of Pharmacoepidemiology and Pharmacovigilance, Medicines for Human Use DepartmentSpanish Agency for Medicines and Medical Devices (AEMPS)MadridSpain
  4. 4.Signal Detection and Data Analysis, Pharmacovigilance and Risk ManagementEuropean Medicines Agency (EMA)LondonUK
  5. 5.Merck KGaAGenevaSwitzerland
  6. 6.Statens Serum InstituteNational Institute for Health Data and Disease ControlCopenhagenDenmark
  7. 7.Department of Clinical Pharmacy, Division Laboratory and PharmacyUniversity Medical Center UtrechtUtrechtThe Netherlands
  8. 8.Division Clinical Pharmacy & EpidemiologyUniversity of BaselBaselSwitzerland
  9. 9.Institute for Medical Information Sciences, Epidemiology, and BiometryLudwig-Maximilians-Universitaet MünchenMunichGermany
  10. 10.Department of Clinical Pharmacology, School of Medicine, Faculty of HealthWitten/Herdecke UniversityWittenGermany
  11. 11.Philipp Klee-Institute for Clinical PharmacologyHELIOS Clinic WuppertalWuppertalGermany
  12. 12.EpidemiologyPfizer Ltd.TadworthUK
  13. 13.Spanish Center for Pharmacoepidemiological Research (CEIFE)MadridSpain
  14. 14.AstraZeneca ABMölndalSweden
  15. 15.MRC Epidemiology Resource CentreSouthampton General HospitalSouthamptonUK
  16. 16.School CAPHRIMaastricht UniversityMaastrichtThe Netherlands
  17. 17.Global Clinical EpidemiologyNovartis Pharma AGBaselSwitzerland
  18. 18.Epidemiology, Medical DivisionPfizerNew YorkUSA
  19. 19.Julius Center for Health Sciences and Primary CareUniversity Medical Center Utrecht (UMCU)UtrechtThe Netherlands
  20. 20.Clinical Pharmacology UnitUniversity Hospital Príncipe de AsturiasMadridSpain

Personalised recommendations